Patient description: A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow: A wellbeing, well-nourished man, non-icteric, cooperative and alert Weight: 73 kg Height: 177 BP: 120/80 HR: 90/min RR: 22/min Hgb: 13 g/dl WBC: 8000 /mm3 (Neutrophil: 2700/mm3) Plt: 300000 /ml AST: 40 U/L ALT: 56 U/L Alk P: 147 U/L Bill total: 1.2 mg/dl ESR: 120 mm/hr MPO-ANCA: 153 EU

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Multiple Organ Dysfunction Syndrome Main Patients with established, unresolving, refractory MODS, in whom all reversible and treatable causes of persistent MODS have been treated or ruled out Patients under endotracheal intubation and mechanical ventilation for at least 7 days Aggregate Multiple Organ Dysfunction Score (5) of greater than 8 over the first seven days of mechanical ventilation and greater than 5 on the day of inclusion Written informed consent to participate in the trial signed by next of kin or other authorized person. Additional Main cause or disease at admission: Adequate "source control" is required and refers to optimal, complete, and definitive surgical and/or medical therapy Infections: 1. Infectious causes of persistence of MODS have reasonably been ruled out on clinical or other grounds (infectious endocarditis, undrained abscesses like sinusitis, empyema or abdominal pus). Consider sampling for culture of broncho-alveolar lavage fluid, protected specimen brush or other (empyema fluid, lung tissue) in order to rule out respiratory infection, as well as intra-vascular catheter change and culture. 2. Present or previous infections, either documented or strongly suspected, have been treated for at least 3 days before inclusion Supportive Care: Optimal hemodynamic, renal, hematologic, nutritional "supportive care" is provided  Decision not to provide full support Immune status and steroid therapy. 1. Steroid therapy Currently indicated for chronic or concurrent disease (meningitis, auto-immune disease, asthma, acute exacerbation of chronic obstructive pulmonary disease [COPD], or other). Inhaled steroids are allowed Administered during current admission (> 20 mg/day of 6-methyl-prednisolone or equivalent for >48 hours) Chronic steroid therapy prior to current admission (> 20 mg of 6-methyl-prednisolone or equivalent/day for > 1 month during previous 3 months). 2. Other immune-suppressive therapy within the previous 6 months. 3. Known AIDS. 4. Neutropenia < 500/mcl. 5. Preceding organ transplantation Irreversible and or ultimately fatal clinical conditions like metastatic malignant disease or cardiogenic shock caused by coronary artery disease Presence of invasive fungal infection Other significant pre-existing underlying chronic diseases: 1. Severe parenchymal liver disease (Child-Pugh grade C) 2. Severe and irreversible acute or chronic central nervous system disease. 3. Severe end-stage chronic obstructive pulmonary disease (home oxygen or more than 1 exacerbation in previous year) 4. End-stage renal disease (Chronic dialysis) Age less than 18 years Pregnancy